Analyst
Piper Sandler
Equibles does not estimate personal net worth.
Karan Patel is recorded as Analyst at Piper Sandler. Karan Patel has spoken on 4 earnings calls across 2 companies, most recently for Fulgent Genetics, Inc. on November 5, 2026. Those appearances were for Fulgent Genetics, Inc. (FLGT) and GRAIL, Inc. (GRAL). The companies whose calls Karan Patel spoke on are classified in the Healthcare sector.
“To start off, I had a couple questions on the billing transition. It sounds like there's still some work to be done, but we have seen improvement. I guess, can you maybe quantify what inning we may be in there and what kind of... You know, site we have into, into when that may be done and fully transitioned.”
“I guess maybe going back to FDA and possible label restriction, I guess, can you provide any sort of color guidance into... Thoughts on an upper bound age restriction and what share of volume comes from the 65 and above cohort and then the 50 to 65 band as well?”
“If you could speak to the Illumina royalty resuming some time in Q4, how can we think about margins for Q4 and then specifically for full year 27?”
“I guess I'll start with some of the RCM transition issues. Maybe if you could help us pinpoint what specifically in this final phase is causing these maybe delayed issues, and do you have maybe an estimated timeline for resolution here?”
Piper Sandler
Analyst
Transcript header (unverified)
Diagnostics & Research · Healthcare
GRAL
Diagnostics & Research · Healthcare
